SELLAS Life Sciences Group, Inc. SLS
8.42 USD +0.05 (+0.60%)
At closeNov 11, 2026, 7:52 PM EST
8.33 -0.09 -1.07%
After hours · Nov 11, 7:52 PM ET
8.09 Day range 8.59
1.39 52-week range 15.88
- YTD
- +123.34%
- 1 year
- +457.62%
News
benzinga.com SELLAS Life Sciences To Present Data From Completed Phase 2 Study Of SLS009 For Treatment Of R/R AML, At 68th ASH Annual Meeting And Exposition − Company to present Phase 2 clinical data evaluating SLS009 (tambiciclib) in combination with azacitidine and venetoclax in patients who have previously failed venetoclax-based therapy − − Patients…
globenewswire.com SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026 − Company to present Phase 2 clinical data evaluating SLS009 (tambiciclib) in combination with azacitidine and venetoclax in patients who have previously failed venetoclax-based therapy − − Patients…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
benzinga.com SELLAS Life Sciences Stock Stumbles: What's Going On? SELLAS Life Sciences Group shares are falling Wednesday as the company's Phase 3 leukemia study moves toward its final analysis.
benzinga.com SELLAS Life Sciences Announces Its Pivotal Phase 3 Study Of Galinpepimut-S In Acute Myeloid Leukemia Participants Surpasses Pre-Specified 80th Event SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS’’ or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer
globenewswire.com SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia - Reaching the Pre-Specified 80 th Event Triggers the Final Analysis of the Pivotal Phase 3 Trial -
defenseworld.net SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 11.2% – Here’s What Happened SELLAS Life Sciences Group, Inc. (NASDAQ: SLS - Get Free Report)'s stock price fell 11.2% during mid-day trading on Friday. The stock traded as low as $9.75 and last traded at $10.0740. Approximately…
gurufocus.com SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier Study SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier StudyPR NewswireSTOCKHOLM, Oct. 15, 2026STOCKHOLM, Oct. 15, 2026 /PRNewswire/ -- SciBa
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. (“Sellas” or the “Company”) (NASDAQ: SLS). Such investors…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ: SLS). Such investors are…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. (“Sellas” or the “Company”) (NASDAQ: SLS). Such investors…
benzinga.com SELLAS Life Sciences Announces Preclinical Data Demonstrating SLS009 Synergy And Activity In MYC-Amplified Pancreatic Cancer Models SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model - Combination of SLS009 and daraxonrasib…
globenewswire.com SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ: SLS).
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. (“Sellas” or the “Company”) (NASDAQ: SLS). Such investors…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ: SLS).
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. (“Sellas” or the “Company”) (NASDAQ: SLS).
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics…- benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ: SLS).
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. (“Sellas” or the “Company”) (NASDAQ: SLS). Such investors…
gurufocus.com Power Metallic Defines High-Grade Maiden Resource at Lion Averaging ~3.9% CuEq, with >85% Indicated and Significant Expansion Potential Power Metallic Defines High-Grade Maiden Resource at Lion Averaging ~3.9% CuEq, with >85% Indicated and Significant Expansion Potential
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ: SLS).
benzinga.com SELLAS Life Sciences Says Three Abstracts Evaluating SLS009, Potent, Selective CDK9 Inhibitor, In Preclinical Models Of PDAC Accepted For Poster Presentation At AACR Conference On Pancreatic Cancer - Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the…
globenewswire.com SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer - Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. (“Sellas” or the “Company”) (NASDAQ: SLS). Such investors…
benzinga.com SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED) Short seller BMF Capital disclosed a short position in SELLAS Life Sciences, arguing the market has 'dangerously overvalued' the biotech.
benzinga.com Benzinga Bulls and Bears: Nvidia, CrowdStrike, Intuit Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
benzinga.com When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges SELLAS Life Sciences Group Inc. (NASDAQ:SLS) stock is trading higher on Thursday. Year-to-date, the stock has surged by around 300%.
benzinga.com When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges SELLAS stock gains momentum following FDA approval for Revolution Medicines, highlighting SLS009 preclinical pancreatic cancer data.- benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
seekingalpha.com This One Data Readout Could Make Or Break Sellas Life Sciences Group SELLAS Life Sciences Group is a high-conviction buy ahead of the pivotal Phase 3 REGAL trial readout for GPS in AML. The unusually long REGAL trial timeline suggests GPS may be delivering a…- benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com SELLAS Life Sciences Gr Q2 EPS $(0.05) Misses $(0.04) Estimate SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 28.57 percent increase over losses…- benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's regular session. The company's market cap stands at $21.6 million. Kalaris Therapeutics (NASDAQ:KLRS)…
benzinga.com ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big gainers: PHOE, SG, TRVI, DCBO, ZNTL, GPRE, SLS, FEIM, TRV, BHVN, KOS, BJRI, MBX.
benzinga.com SELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wall SELLAS Life Sciences Group shares are trading lower Wednesday as investors take profits, with risk appetite softer across equities.
benzinga.com SELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move? SELLAS Life Sciences shares are trading lower Tuesday as traders digest a breakout run, with momentum still elevated from the latest update.
benzinga.com Sellas Life Sciences Shares Break Out To New 52-Week High: What's Driving The Momentum? SELLAS Life Sciences shares are trading higher by about 24% on Monday as the stock extends a breakout run that has traders focused on fresh highs and corporate updates.- benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Iridium Communications, FuelCell Energy, Rocket Lab And Other Big Stocks Moving Higher On Monday Dow Jones gains 350 points, Iridium acquired by Rocket Lab for $8B, big stocks recording gains: QuidelOrtho, FuelCell, Ouster, Viasat, Swarmer, Charter, Prime Medicine, Roblox, Satellogic, Churchill…
benzinga.com SELLAS Stock Hits New Highs: What's Happening Today? SELLAS Life Sciences Group Inc (NASDAQ: SLS) shares are pushing higher Friday morning, extending Thursday’s strong rally.
benzinga.com Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc…
benzinga.com Why SELLAS Life Sciences Stock Is Surging Thursday Shares of SELLAS Life Sciences Group are rallying Thursday, hitting a fresh 52-week high of $11.06 on heavy volume after a regulatory filing.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1…
benzinga.com Jim Cramer: Buy GE Aerospace, 'Two Thumbs Up' For This Life Sciences Stock On Mad Money Lightning Round, Cramer likes Joby Aviation for its spec and US gov. investment in drones. Recommends buying QXO, GE, and BTC.